Glisindamide is a hypoglycemic agent and part of the second-generation sulfonamide derivatives, used as medication to control blood sugar levels in patients with diabetes mellitus type 2. Glisindamide exerts greater binding affinity to sulfonylurea receptor type 1 (SUR1) than the first-generation compounds. It also exerts greater binding affinity for peroxisome proliferator-activated receptor gamma (PPARgamma) agonistic activity.

Nilprazole, a benzimidazole derivative, is used for treatment of gastric ulcers, gastritis and hyperacidity.

Cevoglitazar is a dual agonist for the peroxisome proliferator-activated receptor (PPAR)-alpha and -gamma subtypes. Cevoglitazar was as effective as pioglitazone at improving glucose tolerance, normalizes intramyocellular lipids and reduces body weight gain and adiposity, independent of food intake. Metabolic profiling showed that in the muscle cevoglitazar improves the lipid profile via both PPARα‐ and PPARγ‐mediated mechanisms. Cevoglitazar only induced small changes to the lipid composition of visceral fat. In subcutaneous fat, however, cevoglitazar induced changes similar to those observed with fenofibrate suggesting export of fatty acids from this depot.

Pirifibrate is a fibric acid derivative. Pirifibrate was used in the treatment of hyperlipoproteinemia (HLP). After treatment with pirifibrate, mean plasma levels of cholesterol fell about 20% in types IIa and IIb HLP; triglycerides fell between 30% and 46% in types IIb and IV HLP. Slight increases in alpha-lipoproteins in the three types of HLP were measured. Prebeta-lipoprotein levels fell considerably in types IIb and IV. The variations observed in beta-lipoprotein levels were significant only in type IV, which initially showed low values.

Etintidine is a potent competitive antagonist of histamine H2-receptors. It has a low level of antiandrogenic activity. Etintidine was being investigated in the treatment of peptic ulcer, however, its development has been discontinued.

Sobetirome (3,5-dimethyl-4[(4'-hydroxy-3'-isopropylbenzyl)-phenoxy] acetic acid, also known as GC-1 and QRX-431, is a member of a class of compounds known as selective thyromimetics. It was firstly developed by Thomas Scanlan’s group at the University of California-San Francisco (UCSF) in 1995. Sobetirome binds selectively to the main hepatic form of thyroid hormone (TH) receptor, TRβ1, compared to TRα1, which is principally responsible for thyrotoxic effects on heart, muscle and bone. Sobetirome also preferentially accumulates in liver. It was originally envisaged that sobetirome could be used to stimulate hepatic pathways that lower cholesterol without harmful side effects and might be used in conjunction with statins. Indeed, sobetirome progressed through preclinical animal studies and Phase I human clinical trials with excellent results and without obvious harmful side effects. Sobetirome had been in phase I clinical trials for the treatment of lipid metabolism disorders and obesity. However, this research has been discontinued.

Aleglitazar is a dual agonist of PPARalpha/PPARgamma which was developed by Hoffmann-La Roche for the treatment of type 2 diabetes. Aleglitazar activates PPAR receptors with EC50 in nanomolar range and exerts a cardioprotective effect in vitro. The drug is currently in phase III of clinical trials.

Venritidine [D 16637] is an H2-antagonist which appears to undergo phase I clinical trials in the United Kingdom and preclinical investigation in Germany as a gastric ulcer treatment.

Glicaramide is a compound with anti-diabetic (hypoglycemic) activity. It is a second-generation sulfonylurea with a structure similar to glibenclamide, but with 2-methoxy-5-chlorobenzyl replaced by a cyclic acyl group. Peroxisome proliferator-activated receptor gamma (PPARgamma) agonistic activity of glicaramide has been observed as well. Glicaramide has been suggested to have more pronounced extra-pancreatic effects than glibenclamide or tolbutamide.

ISOTIQUIMIDE is an anti-ulcerative agent.